Sudeep Pharma Share Price Makes Strong Debut, Lists At 23% Premium On NSE, BSE

Sudeep Pharma made a strong debut on the D-Street on November 28, with shares listing at a premium of 23 per cent over the issue price. On the NSE, the pharma stock opened at Rs 730 per share, a premium of 23.10 per cent, and on the BSE, it started trading at Rs 733.95 apiece, a premium of 23.77 per cent.

The strong listing was broadly in line with the grey market, where the stock was quoting a premium of Rs 121, or about 20.4 percent, ahead of its debut.

ICICI Securities and IIFL Capital are the book running lead managers, and MUFG Intime India is the registrar to the issue.

Through the IPO, Sudeep Pharma raised Rs 895 crore through a combination of fresh issue of equity shares worth Rs 95 crore and offer-for-sale (OFS) component aggregating to Rs 800 crore.

Of the Rs 95 crore net proceeds, the pharma company plans to allocate Rs 75.81 crore for procuring machinery for its production line located at Nandesari Facility I and the rest amount for general corporate purposes.

Sudeep Pharma Limited, incorporated in 1989, is a leading manufacturer of pharmaceutical excipients, food-grade minerals and specialty nutrition ingredients. The pharma company sells its products in more than 100 countries and operates six manufacturing facilities with a combined capacity of 50,000 MT.

Its product portfolio includes a wide range of mineral-based ingredients such as calcium, iron, magnesium, zinc, potassium and sodium compounds.

Sudeep Pharma IPO Listing: Here’s How Much Investors Made

Sudeep Pharma opened for public bidding on November 21 and closed on November 25. The company offered its shares with a price band of Rs 563-593 per share in lot sizes of 25 stocks. Minimum investment required by retail investors to apply for one lot of Sudeep Pharma IPO was Rs 14,825 crore.

Based on the upper end of the price band at Rs 593, the stock’s Rs 730 opening on the NSE delivered a listing gain of Rs 137 per share. At the listing price, this would have yielded a profit of Rs 3,425 per lot (25 × Rs 137), before taxes and charges.

Sudeep Pharma IPO Subscription Details

The subscription of Sudeep Pharma IPO was led by qualified institutional buyers (QIBs), who booked the issue 213.08 times their quota. The non-institutional investors (NIIs) and retail investors subscribed the issue 116.72 times and 15.65 times, respectively.

Sudeep Pharma IPO Anchor Investors

Ahead of the IPO launch, Sudeep Pharma raised Rs 268.40 crore from institutional investors in the anchor round. Of the total 4.53 million shares allocated to anchor investors, 3.60 million shares, about 79.64 per cent, were allocated to 14 domestic mutual funds, who applied through a total of 20 schemes.

SBI Healthcare Opportunities Fund, ICICI Prudential MNC Fund, Nippon India Flexi Cap Fund, and Aditya Birla Sun Life Small Cap Fund were among the major buyers, each acquiring 7.82 per cent of the anchor allocation by investing around Rs 21 crore each. Among other marquee investors were HDFC Manufacturing Fund, Axis Small Cap Fund, Motilal Oswal Large Cap Fund, Bandhan Small Cap Fund, and UTI Healthcare Fund.

Sudeep Pharma Financials

Sudeep Pharma reported a total income of 130.08 crore for the quarter ended June 30, 2025. Its profit after tax (PAT) came in at Rs 31.27 crore, and Ebitda stood at Rs 48.57 crore.

For the full financial year FY25, total income stood at Rs 511.33 crore, up from Rs 465.38 crore in FY24 and Rs 438.26 crore in FY23. PAT came in at Rs 138.69 crore, up from Rs 133.15 crore in FY24, and Rs 62.32 crore in FY23. Ebitda stood at Rs 199.28 crore, up from Rs 187.76 in FY24, and Rs 98.64 crore in FY23.

The company's net worth, as of June 30, 2025, stood at Rs 688.32 crore, tripling from Rs 226.29 crore reported in FY23. Its debt stood at Rs 135.97 crore, as of June 30, 2025.